nach oben

Infection

Erschienen in:

13.08.2016 | Brief Report

HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing

verfasst von: T. Ruggiero, E. Burdino, A. Calcagno, S. Bonora, L. Boglione, G. Di Perri, V. Ghisetti

Erschienen in: Infection | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Data on the frequency of HCV naturally occurring drug-resistant variants (RAVs) at baseline in HIV/HCV coinfected patients are scarce.

Methods

NS3-HCV RAVs were studied by full-population direct sequencing from plasma specimens of 345 DAA-naïve patients with HCV chronic hepatitis (159 of them with HIV/HCV-coinfection).

Results

NS3 RAVs were identified in 31.5 % of patients, with a significant proportion of HIV/HCV coinfected DAA-naïve patients compared to those with HCV monoinfection (38 vs. 25 % p = 0.0104, OR 1.84; 95 % CI 1.162–2.916).

Conclusions

HCV resistance genotyping test before treatment may be worth in special populations such as HIV/HCV coinfection to optimize patient treatment.

Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;33:562–9.CrossRef

Molina J-M, Orkin C, Iser DM, Zamora F-X, Nelson M, Stephan C, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015;385:1098–106.CrossRefPubMed

Sarrazin CJ. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504. doi:10.1016/j.jhep.2015.09.011.CrossRefPubMed

Trimoulet P, Belzunce C, Faure M, Wittkop L, Reigadas S, Dupon M, et al. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. HIV Med. 2011;12:506–9.CrossRefPubMed

Silva T, Cortes Martins H, Coutinho R, Leitão E, Silva R, Pádua E. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV. J Med Virol. 2015;87(9):1549–57. doi:10.1002/jmv.24213.CrossRefPubMed

Morsica G, Bagaglio S, Uberti-Foppa C, LA Galli L. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV-HCV coinfected individuals treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2009;51:106–8. doi:10.1097/QAI.0b013e3181a02fda.CrossRefPubMed

Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young K, et al. Naturally occurring dominant resistance mutations to HCV protease and polymerase inhibitors in treatment-naïve patients. Hepatology. 2008;48:1769–78.CrossRefPubMedPubMedCentral

Manns M, Marcellin P, Poordad F, De Araujo ESA, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384:414–26.CrossRefPubMed

Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–65. doi:10.1016/S0140-6736(14)61036-9.CrossRefPubMed

10.

Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62:1623–32.CrossRefPubMed

Titel: HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing
verfasst von: T. Ruggiero
E. Burdino
A. Calcagno
S. Bonora
L. Boglione
G. Di Perri
V. Ghisetti
Publikationsdatum: 13.08.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Infection / Ausgabe 6/2016
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-016-0937-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing

Abstract

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C

False-positive cerebrospinal fluid cryptococcus antigen in Libman–Sacks endocarditis

Measles, mumps, rubella, and varicella seroprevalence in refugees in Germany in 2015

Synchronous multifocal necrotizing fasciitis prognostic factors: a retrospective case series study in a single center

A rare cause of infection, Raoultella planticola: emerging threat and new reservoir for carbapenem resistance

Efficacy of two antiseptic regimens on skin colonization of insertion sites for two different catheter types: a randomized, clinical trial

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin